Johns Hopkins Technology Ventures

Executive Director Christy Wyskiel oversees the entire commercialization pipeline, reporting directly to the university president. A specialized licensing and ventures team, drawn from technology-transfer professionals with deep bench expertise in life sciences and engineering, manages individual deal diligence and startup formation. Investment allocations from the university's proof-of-concept funds are approved internally through a faculty-led review committee rather than a traditional investment committee model.

All deal flow originates inside Johns Hopkins University. Faculty, postdocs, and graduate students disclose roughly 500 inventions annually through the technology-transfer office. JHTV then triages these disclosures, filing on the most commercially promising. Because Hopkins spends over $3.4 billion on research each year, the raw discovery pipeline is the deepest in American academia, and JHTV enjoys effectively exclusive first look at any patentable asset developed with university resources.

It is a university technology-transfer office and startup incubator rolled into one. JHTV is a division of Johns Hopkins University, not a standalone venture firm. It deploys grant capital from university and philanthropic sources rather than limited-partner commitments, and its mandate extends beyond investing — it manages the university's intellectual-property portfolio, prosecutes patents, and negotiates industry licenses.

JHTV focuses exclusively on the earliest stage: proof-of-concept, pre-seed, and seed. Its vehicles, including the Louis B. Thalheimer Fund, bridge the gap between NIH or NSF research funding and a startup's first institutional venture round. JHTV rarely leads later-stage rounds but often retains equity stakes that carry into Series A and B financings led by external syndicates.

Only direct deals. JHTV puts capital directly into startup spinouts and occasionally forms strategic licensing partnerships with established companies. It does not commit to external venture funds as an LP, which keeps the entire investment operation tightly aligned to Hopkins-originated intellectual property.

The portfolio concentrates on life sciences — including therapeutics, diagnostics, and medical devices — and related health-adjacent areas such as digital health and healthcare IT. A smaller but active allocation covers engineering and enterprise software. JHTV generally does not invest in consumer internet, fintech, or companies without a clear lineage to a Hopkins lab discovery.

JHTV's capital comes from dedicated innovation and philanthropic grants, not the endowment. The university endowment, managed by the university's investment office, follows a traditional multi-asset-class strategy and does not hold direct equity in Hopkins spinouts. A conflict-of-interest management plan governs faculty founders who may also receive equity, ensuring arm's-length governance between the startup and the university.